

DRUG: Enoxaparin (Lovenox) or Low Molecular Weight Heparin

THERAPY: Home (Outpatient) Treatment of Deep Vein Thrombosis
Prophylaxis of Venous Thromboembolism
Perioperative Bridging for Chronic Oral Anticoagulation

REQUIRED BASELINE INFORMATION:

- ☐ CBC with platelets
- ☐ serum creatinine
- ☐ patient weight (kg)
- ☐ blood pressure

QUANTITY/DURATION OF THERAPY:

*No prior authorization required for initial 5 days (10 dosages) of therapy.
Prior authorization required for refill per established criteria.*

EXCLUSION:

- Hypersensitivity to heparin or low molecular weight heparin products
- Hypersensitivity to pork products
- (+) in vitro test for anti-platelet antibody associated with thrombocytopenia
- history of heparin-induced thrombocytopenia
- platelet count less than 150,000
- active major bleeding
- surgery or acute bleeding event within 30 days
- history of intracranial hemorrhage or neoplasm
- end-stage renal disease requiring dialysis
- calculated creatinine clearance (CrCL) less than 30 mL/min
- patient weight less than 45kg (female) or 57kg (male)
- pregnant patient with mechanical prosthetic heart valve replacement
- increased hemorrhagic risk including (patient-specific)
 - ☐ congenital or acquired bleeding disorder
 - ☐ active ulceration and angiodysplastic gastrointestinal disease
 - ☐ hemorrhagic cerebral vascular accident
 - ☐ recent brain, spinal or ophthalmological surgery
 - ☐ bacterial endocarditis
 - ☐ severe uncontrolled hypertension
- Suspected or proven pulmonary embolism (PE)
- History of failed heparin therapy
- History of non-compliance with medical care and/or medications
- Communication barriers (no telephone, rural location, transient)
- Greater than 15 minutes from emergency services
- Current history of alcohol abuse
- Known risk of falls

INCLUSION:

Acute Deep Vein Thrombosis

- ☐ documented DVT by objective measures
- ☐ enrollment in established home health care program or resident at care facility
- ☐ established medical care for follow-up or resident at care facility
- ☐ concurrent oral anticoagulation therapy (warfarin) initiated Day #1

Prophylaxis of VTE

- ☐ status post qualifying procedure
 - total knee arthroplasty (TKA)
 - total hip arthroplasty (THA)
 - lower extremity trauma (pelvic and/or acetabular fracture) + non-weight bearing
 - spinal cord injury
 - abdominal surgery + non-ambulatory
- ☐ enrollment in established home health care program or residency at care facility
- ☐ concurrent oral anticoagulation therapy (warfarin) initiated Day #1
(if prophylaxis indicated beyond 96 hours)

Perioperative Bridging for Chronic Oral Anticoagulation

- ☐ qualifying high-risk indication necessitating perioperative bridging
 - mechanical mitral heart valve (high-risk)
 - mechanical aortic heart valve (intermediate-risk)
 - mechanical mitral or aortic cage-ball valve (high-risk)
 - antiphospholipid syndrome (high-risk)
 - malignancy with associated thromboembolic risk (high-risk)
 - acute venous thromboembolic event within 90 days (high-risk)
 - acute arterial thromboembolic event within 30 days (high-risk)
 - acute pulmonary embolism within 90 days (high-risk)
 - atrial fibrillation with history of associated cerebral vascular accident (high-risk)
- ☐ qualifying invasive procedure with high-risk of bleeding complications
 - colonoscopy with anticipated polypectomy (excluding screening colonoscopy)
 - central nervous system (CNS) surgery
 - vascular surgery
 - major thoracic, abdominal or pelvic surgery
 - high bleeding risk patient-specific surgical procedure (documentation required)
(excluding dental procedures, cutaneous surgery and cataract surgery)
- ☐ warfarin stopped 5 days before scheduled procedure date
- ☐ low molecular weight heparin (1mg/kg Q12hr) initiated 36 hours after last warfarin dose
- ☐ low molecular weight heparin stopped 12 – 24 hours prior to procedure
- ☐ re-initiate low molecular weight heparin + warfarin 24 hours after procedure

Medical Director _____

Date: _____